Pharmacy Benefit Plan Design for 2026: Copay Structures, Coinsurance Tiers, and Specialty Carve-Outs That Actually Control Spend

Your $140 PMPM Plan: What’s Driving the Cost?

Last quarter, I reviewed claims for a 900-employee tech company that hit $140 PMPM in pharmacy spend, well above the $100-$120 PMPM benchmark for self-funded plans their size. Their generic dispensing rate looked healthy at 91.5%. Despite that, annual pharmacy spend tipped $1.5 million. If your gut reaction is to blame high-cost specialty drugs, you’re probably right, but plan design made things worse. A 3-tier copay structure with flat $10/$40/$100 copays, no coinsurance for specialty, and full pharmacy coverage inside the medical plan led to unchecked utilization and little cost control on high-cost meds.

I’ve seen this scenario play out in manufacturers, nonprofits, and professional services groups. Tweaking copays feels simple, but the real impact lies in understanding which structures blunt trend and which just push cost onto employees with no real savings. Let’s talk about how you can rework your design for 2026 without alienating members or chasing phantom savings.

Copay Amounts: Small Changes, Big Missed Opportunities

Many benefits teams adjust copay levels each renewal, especially when facing a rate hike. Raise generics from $10 to $15, brands from $40 to $50, specialty from $100 to $150. Yet, unless these changes are paired with plan design that influences actual utilization, they do more to shift costs than cut them. For example, most employees taking a $600 brand drug each month aren’t going to stop because the copay rose $10, they will just pay more, or worse, struggle with adherence.

Instead, consider whether your tiers align with the medications driving spend. A 3-tier plan treats all non-preferred brands the same, even if one is a $40 per month statin and another is a $1,100 GLP-1 (think semaglutide). Adding a fourth tier for “specialty” or “non-essential” drugs tightens control. In a 2,000-life plan I consulted for in 2023, moving GLP-1s and certain dermatology drugs to a non-essential fourth tier (50% coinsurance, up to $500) freed up $200,000 in plan spend, even as member out-of-pocket caps protected those with clinical need.

Transparent communication is important here. Benefits teams should use precise language, “GLP-1s for weight loss will have higher member cost sharing in 2026”, and link education to clinical appropriateness. If you plan to move drugs between tiers, anchor those changes to clear clinical or cost criteria. Otherwise, you’ll field frustrated calls from employees and the C-suite alike.

Coinsurance and Specialty: Know When Flat Copays Backfire

Flat copays for specialty drugs were standard ten years ago. Today, they’re a red flag in actuarial models. The median annual cost of a specialty script now sits at $84,000, driven by drugs like Humira ($34,000/year) and new launches in oncology, neurology, and rare disease. Plans that rely solely on a $100 or even $250 specialty copay see runaway liability when 2-3 new utilizers join, often after a high-dollar diagnosis.

Coinsurance, structured at 20-30% of cost up to a reasonable dollar maximum ($250-$500), moderates plan risk and qualifies members for manufacturer copay support. In a recent carve-out for a financial services client (1,500 employees, $1.7M pharmacy spend), replacing flat specialty copays with 25% coinsurance (max $350) allowed us to trigger $90,000 in manufacturer copay assistance, as documented in tools like RxSaver.ai. The plan’s net specialty spend dropped 8% year over year, with no drop in adherence for high-value therapies.

Some plans hesitate to add coinsurance, fearing member backlash. Here’s what I tell clients: most specialty scripts today are filled at specialty pharmacies with robust patient assistance teams. Manufacturer programs like AbbVie myAbbVie Assist (Humira) or Lilly Insulin Value Program can make out-of-pocket zero for qualifying members. The plan, meanwhile, claims the savings. Just be sure your PBM or pharmacy partner is contractually obligated to pass through these dollars.

Specialty Carve-Outs and White Bagging: When to Carve, When to Integrate

The idea of carving out specialty pharmacy, sending those claims to a dedicated specialty vendor instead of the traditional PBM or the medical benefit, has picked up steam. Employers see headlines about 15-20% specialty savings and think it’s easy money. In reality, carve-outs work best for groups with 500+ employees and a predictable specialty population. For a 300-life manufacturing group with only six specialty utilizers, you may not see enough volume to offset vendor fees and disruption.

Where carve-outs do pay off is with drugs administered in hospital outpatient settings. White bagging, where the specialty pharmacy ships patient-specific medication to the hospital for administration, can cut markup by 30-50%. In one recent scenario, a client paying $22,000 per infusion for an oncology drug (billed under medical) cut monthly spend to $12,000 through a white bagging carve-out.

The catch? Hospitals may refuse outside drugs, and some therapies are medically inappropriate for white bagging. Always map out your top 10 specialty drug claims by site of care and NDC before pursuing carve-outs. For more clinical details, resources like ClinicalRx.ai can help your PBM or consultant validate which drugs are “carve-out eligible.”

Building a 2026 Plan That Actually Bends Trend

No single plan design move will offset every cost driver. But smart structuring of copay tiers, targeted coinsurance for specialty, and selective carve-outs changes the cost curve. For employers stuck at $130-$150 PMPM, moving to a four-tier pharmacy structure, generics, preferred brands, non-preferred brands, specialty/non-essential, typically produces 6-10% trend moderation over two years. On a $1.5M annual pharmacy spend, that’s $90,000 to $150,000 back in the budget.

You won’t see those savings unless your PBM contract supports them. That means pass-through of manufacturer assistance, transparent ingredient cost pricing, and data access for real analysis. Independent and transparent PBMs like Capital Rx, SmithRx, and RxBenefits structure contracts for this level of employer control. You can benchmark pharmacy contract terms at RxPBM.ai to avoid surprises at audit time.

Finally, don’t underestimate change management. Explaining why semaglutide is moving to a higher tier, or why specialty drugs are now subject to coinsurance, requires education from HR, not just a revised plan booklet. I recommend engaging your pharmacy benefits consultant early, mapping the clinical and financial rationale, and preparing a member Q&A before open enrollment.

Too many plans chase the “latest thing” in pharmacy design and end up with more complaints but little actual savings. Focus on targeted plan levers, data-driven contract management, and clear communication. In my experience, that’s what distinguishes the CFO who wins a renewal negotiation from the one who’s blindsided by a million-dollar specialty claim.